Chlorpheniramine Maleate, Dextromethorphan HBr, Glyceryl Guaiacolate.
Each 5-mL syrup contains Dextromethorphan HBr 10 mg, Glyceryl Guaiacolate 100 mg and Chlorpheniramine Maleate 1 mg.
Pharmacology: Dextromethorphan HBr is a cough suppressant which reduces cough frequency. Glyceryl guaiacolate is used as an expectorant and has a sputum-thinning effect. The addition of chlorpheniramine maleate is useful in case of cough due to allergy. The sedative side effect of chlorpheniramine maleate has an advantage in the treatment of cough.
Pharmacokinetics: Dextromethorphan HBr: Following oral administration, dextromethorphan is well absorbed. The peak plasma concentration is reached 2 hrs after administration, whereas the maximum clinical effect occurs 5-6 hrs after ingestion of dextromethorphan tablets.
Dextromethorphan is extensively metabolized in the liver and the main metabolite is dextrorphan. About 50% of a dose is excreted in the urine over 24 hrs. Less than 1% of the dose is excreted in the feces. About 8% of the dose is excreted as unchanged drug in the urine in 6 hrs. It is not known if dextromethorphan or dextrorphan is excreted in breast milk or crosses the placenta.
Chlorpheniramine Maleate: Chlorpheniramine maleate is well absorbed after oral administration and distributed into the tissues.
Chlorpheniramine maleate appears to undergo moderate first-pass metabolism and there may be an enterohepatic circulation.
Considerable intersubject variation has been found in the metabolism and excretion of chlorpheniramine maleate and the excretion was dependent on urinary pH and flow rate. About 35% of a dose was excreted as unchanged, 22% as the desmethyl metabolite and 3-10% as didesmethyl metabolite. None of the metabolites are toxic or responsible for clinical antihistaminic effect. In children, there was evidence that suggests of more rapid and complete oral absorption and faster clearance.
Glyceryl Guaiacolate: Glyceryl guaiacolate is readily absorbed from the gastrointestinal tract, with plasma half-life of approximately 1 hr. Glyceryl guaiacolate is rapidly metabolized by oxidation to β-(2-methoxy-phenoxy) lactic acid. About 40% of the dose is excreted as metabolite in the urine in 3 hrs.
For the relief of cough, sneezing, congestion due to minor throat and bronchial irritation.
Adults: 1 tsp 3 times daily.
Children 6-12 years: ½ tsp 3 times daily.
Konidin Cough Suppressant should not be used in patients known to be hypersensitive to components of this product.
Konidin Cough Suppressant syrup is not recommended for pertussis, bronchial asthma or chronic cough unless directed by a physician.
Do not take higher than recommended doses.
Effects on the Ability to Drive or Operate Machinery: During therapy of Konidin Cough Suppressant syrup, do not drive or operate machinery.
Use in children: Konidin Cough Suppressant syrup is not recommended for children <2 years except under a physician's direction.
For pregnant women and breastfeeding mothers, it is suggested that Konidin Cough Suppressant syrup should be taken under a physician's direction.
Nausea, gastrointestinal disturbance and drowsiness.
Konidin Cough Suppressant syrup should not be taken concomitantly with monoamine oxidase inhibitors.
R05FA02 - opium derivatives and expectorants ; Belongs to the class of combinations of opium derivatives cough suppressants and expectorants. Used in the treatment of cough.